SpringerLink
Log in

Polypharmacy and bone fracture risk

  • Letter to the Editor
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Wakasugi M, Yokoseki A, Wada M, Momotsu T, Sato K, Kawashima H, et al (2021) Polypharmacy, chronic kidney disease, and incident fragility fracture: a prospective cohort study. J Bone Miner Metab

  2. Komorita Y, Ohkuma T, Iwase M, Fujii H, Oku Y et al (2021) Polypharmacy and bone fracture risk in patients with type 2 diabetes: the Fukuoka Diabetes Registry. Diabetes Res Clin Pract 181:109097

    Article  Google Scholar 

  3. Tran T, Bliuc D, Hansen L, Abrahamsen B, van den Bergh J et al (2018) Persistence of excess mortality following individual nonhip fractures: a relative survival analysis. J Clin Endocrinol Metab 103:3205–3214

    Article  Google Scholar 

  4. Koseki H, Sunagawa S, Noguchi C, Yonekura A, Matsumura U et al (2021) Incidence of and risk factors for hip fracture in Nagasaki, Japan from 2005 to 2014. Arch Osteoporos 16:111

    Article  Google Scholar 

  5. Lai SW, Liao KF, Liao CC, Muo CH, Liu CS, Sung FC (2010) Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. Medicine 89:295–299

    Article  Google Scholar 

Download references

Funding

The authors received no funding from an external source.

Author information

Authors and Affiliations

  1. Department of Public Health, College of Public Health, and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan

    Shih-Wei Lai

  2. Department of Occupational Safety and Health, College of Public Health, China Medical University, Taichung, Taiwan

    Bing-Fang Hwang

  3. School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan

    Chiu-Shong Liu

  4. College of Medicine, Tzu Chi University, Hualien, Taiwan

    Kuan-Fu Liao

  5. Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan

    Shih-Wei Lai & Chiu-Shong Liu

  6. Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi Hospital, No. 66, Sec. 1, Fongsing Road, Tanzi District, Taichung City, 427, Taiwan

    Kuan-Fu Liao

Authors
  1. Shih-Wei Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bing-Fang Hwang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chiu-Shong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kuan-Fu Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kuan-Fu Liao.

Ethics declarations

Conflict of interest

The authors disclose no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lai, SW., Hwang, BF., Liu, CS. et al. Polypharmacy and bone fracture risk. J Bone Miner Metab 40, 535–536 (2022). https://doi.org/10.1007/s00774-021-01307-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-021-01307-1

Search

Navigation